For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Tax benefit | - | - | 0 | - |
| Administration expenses | 3,628,173 | 4,598,574 | 3,585,351 | 53,068,147 |
| Occupancy expenses - related party | 6,600 | 14,789 | 6,373 | 6,469 |
| Research and development | 19,961 | 60,201 | 53,522 | 54,097 |
| Total operating expenses | 3,654,734 | 4,673,564 | 3,645,246 | 53,128,713 |
| Loss from operations | -3,654,734 | -4,673,564 | -3,645,246 | -53,128,713 |
| Interest expense | 58,955 | 305,649 | 254,542 | 104,042 |
| Interest income | 37 | 19 | 7 | 1 |
| Derivative expense | - | - | 238,584 | 59,271 |
| Change in fair value of derivative liabilities | 87,728 | -19,706 | 98,963 | 47,119 |
| Change in fair value of warrant liability | -593,710 | - | - | - |
| Other expense | 54,000 | - | - | - |
| Gain (loss) on extinguishment of debt, net | 14,317 | 195,861 | -31,000 | -809,954 |
| Foreign currency transaction gain (loss) | -19,497 | -34,699 | -1,059 | -12,486 |
| Total other income (expense), net | 563,340 | -164,174 | -426,215 | -938,633 |
| Loss before taxes | -3,091,394 | -4,837,738 | -4,071,461 | -54,067,346 |
| Net Income Loss | -3,091,394 | -4,837,738 | -4,071,461 | -54,067,346 |
| Deemed dividend | 932,246 | - | 0 | - |
| Net loss | -4,023,640 | - | -4,071,461 | -54,067,346 |
| Unrealized foreign currency translation loss (gain) | -7,846 | 17,044 | -145,640 | -27,311 |
| Total other comprehensive income (gain) | -7,846 | 17,044 | -145,640 | -27,311 |
| Total comprehensive loss | -4,031,486 | -4,820,694 | -4,217,101 | -54,094,657 |
| Basic EPS | -0.3 | -0.39 | -1.063 | -12.5 |
| Diluted EPS | -0.3 | -0.39 | -1.063 | -12.5 |
| Basic Average Shares | 13,360,358 | 12,331,526 | 3,968,176* | 4,325,994 |
| Diluted Average Shares | 13,360,358 | 12,331,526 | 3,968,176* | 4,325,994 |
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB)